Association between plasma levels of hyaluronic acid and functional outcome in acute stroke patients

Journal of Neuroinflammation

Volumn 11, Issue , 2014, Pages

  Tang, Sung Chun ^a   Yeh, Shin Joe ^a   Tsai, Li Kai ^a   Hu, Chaur Jong ^b   Lien, Li Ming ^c   Peng, Giia Sheun ^d   Yang, Wei Shiung ^a,e   Chiou, Hung Yi ^f   Jeng, Jiann Shing ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b TAIPEI MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^c SHIN KONG WU HO SU MEMORIAL HOSPITAL   (Taiwan)

^d TRI SERVICE GENERAL HOSPITAL   (Taiwan)

^e NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^f TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Acute stroke; Hyaluronic acid; Intracerebral hemorrhage; Ischemic stroke

Indexed keywords

HYALURONIC ACID;

ADULT; AGE DISTRIBUTION; ARTICLE; BLOOD LEVEL; BODY MASS; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CARBOHYDRATE SYNTHESIS; CASE CONTROL STUDY; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN CELL; HYALURONIC ACID LEVEL; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; RANKIN SCALE; SCORING SYSTEM; AGED; BLOOD; CEREBRAL HEMORRHAGE; CLINICAL TRIAL; COMPLICATION; MIDDLE AGED; MULTICENTER STUDY; OUTCOME ASSESSMENT; PREDICTIVE VALUE; SEVERITY OF ILLNESS INDEX; TAIWAN; TIME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; CEREBRAL HEMORRHAGE; FEMALE; HUMANS; HYALURONIC ACID; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); PREDICTIVE VALUE OF TESTS; SEVERITY OF ILLNESS INDEX; STROKE; TAIWAN; TIME FACTORS;

EID: 84903218578     PISSN: None     EISSN: 17422094     Source Type: Journal    
DOI: 10.1186/1742-2094-11-101     Document Type: Article

References (43)

1. Feigin VL, Lawes CM, Bennett DA, Barker-Collo SL, Parag V. Worldwide stroke incidence and early case fatality reported in 56 population-based studies: a systematic review. Lancet Neurol 2009, 8:355-369. 10.1016/S1474-4422(09)70025-0, 19233729.
2. Feigin VL, Lawes CM, Bennett DA, Anderson CS. Stroke epidemiology: a review of population-based studies of incidence, prevalence, and case-fatality in the late 20th century. Lancet Neurol 2003, 2:43-53. 10.1016/S1474-4422(03)00266-7, 12849300.
3. Woodruff TM, Thundyil J, Tang SC, Sobey CG, Taylor SM, Arumugam TV. Pathophysiology, treatment, and animal and cellular models of human ischemic stroke. Mol Neurodegener 2011, 6:11. 10.1186/1750-1326-6-11, 3037909, 21266064.
4. Eltzschig HK, Eckle T. Ischemia and reperfusion - from mechanism to translation. Nat Med 2011, 17:1391-1401. 10.1038/nm.2507, 3886192, 22064429.
5. Rincon F, Mayer SA. Novel therapies for intracerebral hemorrhage. Curr Opin Crit Care 2004, 10:94-100. 10.1097/00075198-200404000-00003, 15075717.
6. Auer RN, Sutherland GR. Primary intracerebral hemorrhage: pathophysiology. Can J Neurol Sc 2005, 32(Suppl 2):S3-S12.
7. Delgado P, Cuadrado E, Rosell A, Alvarez-Sabín J, Ortega-Aznar A, Hernández-Guillamón M, Penalba A, Molina CA, Montaner J. Fas system activation in perihematomal areas after spontaneous intracerebral hemorrhage. Stroke 2008, 39:1730-1734. 10.1161/STROKEAHA.107.500876, 18403741.
8. Wang YX, Yan A, Ma ZH, Wang Z, Zhang B, Ping JL, Zhu JS, Zhou Y, Dai L. Nuclear factor-kappaB and apoptosis in patients with intracerebral hemorrhage. J Clin Neurosci 2011, 18:1392-1395. 10.1016/j.jocn.2010.11.039, 21782444.
9. Hermann DM, Chopp M. Promoting brain remodelling and plasticity for stroke recovery: therapeutic promise and potential pitfalls of clinical translation. Lancet Neurol 2012, 11:369-380. 10.1016/S1474-4422(12)70039-X, 3964179, 22441198.
10. Zhang ZG, Chopp M. Neurorestorative therapies for stroke: underlying mechanisms and translation to the clinic. Lancet Neurol 2009, 8:491-500. 10.1016/S1474-4422(09)70061-4, 2727708, 19375666.
11. Licata G, Tuttolomondo A, Corrao S, Di Raimondo D, Fernandez P, Caruso C, Avellone G, Pinto A. Immunoinflammatory activation during the acute phase of lacunar and non-lacunar ischemic stroke: association with time of onset and diabetic state. Int J Imunopathol Pharmacol 2006, 19:639-646.
12. Tuttolomondo A, Di Raimondo D, Pecoraro R, Arnao V, Pinto A, Licata G. Atherosclerosis as an inflammatory disease. Curr Pharm Des 2012, 18:4266-4288. 10.2174/138161212802481237, 22390643.
13. Lambertsen KL, Biber K, Finsen B. Inflammatory cytokines in experimental and human stroke. J Cereb Blood Flow Metab 2012, 32:1677-1698. 10.1038/jcbfm.2012.88, 3434626, 22739623.
14. Kamel H, Iadecola C. Brain-immune interactions and ischemic stroke: clinical implications. Arch Neurol 2012, 69:576-581. 10.1001/archneurol.2011.3590, 3586409, 22782509.
15. Iadecola C, Anrather J. The immunology of stroke: from mechanisms to translation. Nature Med 2011, 17:796-808. 10.1038/nm.2399, 3137275, 21738161.
16. Ceulemans AG, Zgavc T, Kooijman R, Hachimi-Idrissi S, Sarre S, Michotte Y. The dual role of the neuroinflammatory response after ischemic stroke: modulatory effects of hypothermia. J Neuroinflammation 2010, 7:74. 10.1186/1742-2094-7-74, 2988764, 21040547.
17. Wang J. Preclinical and clinical research on inflammation after intracerebral hemorrhage. Prog Neurobiol 2010, 92:463-477. 10.1016/j.pneurobio.2010.08.001, 2991407, 20713126.
18. Tammi MI, Day AJ, Turley EA. Hyaluronan and homeostasis: a balancing act. J Biol Chem 2002, 277:4581-4584. 10.1074/jbc.R100037200, 11717316.
19. Itano N, Kimata K. Mammalian hyaluronansynthases. IUBMB Life 2002, 54:195-199. 10.1080/15216540214929, 12512858.
20. Stern R. Devising a pathway for hyaluronan catabolism: are we there yet?. Glycobiology 2003, 13:105R-115R. 10.1093/glycob/cwg112, 14514708.
21. Fraser JR, Laurent TC, Laurent UB. Hyaluronan: its nature, distribution, functions and turnover. J Intern Med 1997, 242:27-33. 10.1046/j.1365-2796.1997.00170.x, 9260563.
22. Wang A, de la Motte C, Lauer M, Hascall V. Hyaluronan matrices in pathobiologicalprocesses. FEBS J 2011, 278:1412-1418. 10.1111/j.1742-4658.2011.08069.x, 21362136.
23. Nusgens BV. Hyaluronic acid and extracellular matrix: a primitive molecule?. Ann Dermatol Venereol 2010, 137(Suppl 1):S3-S8.
24. Jiang D, Liang J, Noble PW. Hyaluronan as an immune regulator in human diseases. Physiol Rev 2011, 91:221-264. 10.1152/physrev.00052.2009, 3051404, 21248167.
25. Sloane JA, Batt C, Ma Y, Harris ZM, Trapp B, Vartanian T. Hyaluronan blocks oligodendrocyte progenitor maturation and remyelination through TLR2. Proc Natl Acad Sci USA 2010, 107:11555-11560. 10.1073/pnas.1006496107, 2895128, 20534434.
26. Garantziotis S, Li Z, Potts EN, Lindsey JY, Stober VP, Polosukhin VV, Blackwell TS, Schwartz DA, Foster WM, Hollingsworth JW. TLR4 is necessary for hyaluronan-mediated airway hyperresponsiveness after ozone inhalation. Am J Respir Crit Care Med 2010, 181:666-675. 10.1164/rccm.200903-0381OC, 2868499, 20007931.
27. Li Z, Potts-Kant EN, Garantziotis S, Foster WM, Hollingsworth JW. Hyaluronan signaling during ozone-induced lung injury requires TLR4, MyD88, and TIRAP. PLoS One 2011, 6:e27137. 10.1371/journal.pone.0027137, 3208559, 22073274.
28. Krupinski J, Ethirajan P, Font MA, Turu MM, Gaffney J, Kumar P, Slevin M. Changes in hyaluronan metabolism and RHAMM receptor expression accompany formation of complicated carotid lesions and may be pro-angiogenic mediators of intimal neovessel growth. Biomark Insights 2008, 2:361-367. 2717833, 19662229.
29. Adams HP, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, Marsh EE. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke 1993, 24:35-41. 10.1161/01.STR.24.1.35, 7678184.
30. Arumugam TV, Okun E, Tang SC, Thundyil J, Taylor SM, Woodruff TM. Toll-like receptors in ischemia-reperfusion injury. Shock 2009, 32:4-16. 10.1097/SHK.0b013e318193e333, 19008778.
31. Tang SC, Arumugam TV, Xu X, Cheng A, Mughal MR, Jo DG, Lathia JD, Siler DA, Chigurupati S, Ouyang X, Magnus T, Camandola S, Mattson MP. Pivotal role for neuronal Toll-like receptors in ischemic brain injury and functional deficits. Proc Natl Acad Sci U S A 2007, 104:13798-13803. 10.1073/pnas.0702553104, 1959462, 17693552.
32. Tang SC, Yeh SJ, Li YI, Wang YC, Baik SH, Santro T, Widiapradja A, Manzanero S, Sobey CG, Jo DG, Arumugam TV, Jeng JS. Evidence for a detrimental role of TLR8 in ischemic stroke. Exp Neurol 2013, 250:341-347.
33. Wang YC, Wang PF, Fang H, Chen J, Xiong XY, Yang QW. Toll-like receptor 4 antagonist attenuates intracerebral hemorrhage-induced brain injury. Stroke 2013, 44:2545-2552. 10.1161/STROKEAHA.113.001038, 23839500.
34. Sansing LH, Harris TH, Welsh FA, Kasner SE, Hunter CA, Kariko K. Toll-like receptor 4 contributes to poor outcome after intracerebralhemorrhage. Ann Neurol 2011, 70:646-656. 10.1002/ana.22528, 3671585, 22028224.
35. Sloane JA, Blitz D, Margolin Z, Vartanian T. A clear and present danger: endogenous ligands of Toll-like receptors. Neuromolecular Med 2010, 12:149-163. 10.1007/s12017-009-8094-x, 2908951, 19830599.
36. Tang SC, Wang YC, Li YI, Lin HC, Manzanero S, Hsieh YH, Phipps S, Hu CJ, Chiou HY, Huang YS, Yang WS, Mattson MP, Arumugam TV, Jeng JS. Functional role of soluble receptor for advanced glycation end products in stroke. Arterioscler Thromb Vasc Biol 2013, 33:585-594. 10.1161/ATVBAHA.112.300523, 23288172.
37. Onarheim H, Reed RK, Laurent TC. Elevated hyaluronan blood concentrations in severely burned patients. Scand J Clin Lab Invest 1991, 51:693-697. 10.3109/00365519109104582, 1806984.
38. Berg S, Brodin B, Hesselvik F, Laurent TC, Maller R. Elevated levels of plasma hyaluronan in septicaemia. Scand J Clin Lab Invest 1988, 48:727-732. 10.3109/00365518809088752, 3238317.
39. Sallisalmi M, Tenhunen J, Kultti A, Tammi M, Pettila V. Plasma hyaluronan and hemorheology in patients with septic shock: a clinical and experimental study. Clin Hemorheol Microcirc 2014, 56:133-144.
40. Goldberg RL, Huff JP, Lenz ME, Glickman P, Katz R, Thonar EJ. Elevated plasma levels of hyaluronate in patients with osteoarthritis and rheumatoid arthritis. Arthritis Rheum 1991, 34:799-807. 10.1002/art.1780340704, 2059228.
41. West DC, Yaqoob M. Serum hyaluronan levels follow disease activity in vasculitis. Clin Nephrol 1997, 48:9-15.
42. Xi W, Zhou Y, Lv S, Gao Q, Bu G, Wang Y, Cheng G, Xu G. Plasma hyaluronan and collateral development in patients with coronary artery disease. Coron Artery Dis 2010, 21:228-232. 10.1097/MCA.0b013e328338ccf3, 20305548.
43. Sahota P, Savitz SI. Investigational therapies for ischemic stroke: neuroprotection and neurorecovery. Neurotherapeutics 2011, 8:434-451. 10.1007/s13311-011-0040-6, 3250280, 21604061.